- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05580107
MDPK67b in Patients With Prostate Cancer
Open-label Phase Ib Study of Preoperative Treatment With the KLK Inhibitor MDPK67b in Patients With Untreated Prostate Cancer
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Christoph Kündig
- Phone Number: +41 21 566 14 11
- Email: christoph.kundig@med-discovery.com
Study Locations
-
-
-
Zürich, Switzerland, 8091
- Recruiting
- Klinik für Urologie, UniversitätSpital Zürich (USZ)
-
Contact:
- Daniel Eberli, Prof.
- Phone Number: +41 44 255 9619
- Email: daniel.eberli@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Subject screening criteria
- Patients aged 18 years or older.
- Patients who have untreated suspected PCa or PCa under active surveillance (AS) with progression/upgrading.
- Patients who signed a written screening phase ICF.
Subject non-screening criteria
- Patients who have an uncontrolled disease that would unduly increase the risk of toxicity or limit compliance with study requirements in the opinion of the Investigator; including but not limited to: ongoing or active symptomatic infection, uncontrolled diabetes mellitus, diseases of the coagulation system, unstable or uncompensated cardiac, hepatic, renal, respiratory, or psychiatric disease.
- Patients who required a significant change in their concomitant medications during the week prior to screening visit, or who will likely need to have a change in their concomitant medications during the study. This includes any medication other than those required for PCa diagnosis or for RPE.
- Patients who have received prior radiotherapy to the prostate.
- Patients who have had prior exposure to MDPK67b.
- Patients who have participated in another clinical trial within 3 months prior to screening visit, except if in the opinion of the investigator the type of trial does not interfere in any way with the present trial (eg. non-interventional observational trial). In case of doubt, the sponsor's prior approval must be obtained and the decision to include such a patient will be documented in detail.
Non-screening criteria are exclusion criteria for the screening phase.
For the patients not participating in the screening phase (ie patients with previously established PCa diagnosis), all the criteria above shall be checked prior to enrolment in the treatment phase. However, these patients do not have to sign a screening ICF (screening criterion n°3 is not applicable), and for non-screening criterion n°5, the 3-month wash-out period is prior to the inclusion visit in the treatment phase.
Subject inclusion criteria
- Patients who still meet all the eligibility criteria checked at screening visit.
- Patients who have untreated PCa with a Gleason score of 7 (preferably) or higher, with local disease or with metastatic disease (if metastatic, no visceral metastases, no more than five bone or lymph node metastases), and are scheduled to undergo RPE about 3 weeks later.
- Patients with an expected minimal survival time of 12 months.
Patients who have an acceptable organ and marrow function as assessed at the inclusion visit and defined as follows:
- Absolute neutrophil count ≥ 1.5 × 109/L.
- Platelets ≥ 100 × 109/L.
- Hemoglobin ≥ 9 g/dL.
- Total bilirubin ≤ 1.5 × ULN, unless the patient has known Gilbert's syndrome.
- Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN in presence of liver metastasis.
- Serum creatinine ≤ 2.0 × ULN, or GFR ≥ 30 mL/min by Cockcroft-Gault.
- INR <1.5, aPTT < 60 s
- Patients with an ECOG performance status ≤ 1.
- Patients who agree to refrain to donate sperm for the duration of the study.
- Patients who signed a written treatment phase ICF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose
Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level. If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients. |
24 mg or 48 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in blood pressure
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in blood pressure
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in blood pressure
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in blood pressure
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Body temperature
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in body temperature
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in body temperature
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in body temperature
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in respiration rate
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in respiration rate
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in respiration rate
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in respiration rate
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in weight
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in weight
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in weight
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in weight
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in QTc on ECG
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in QTc on ECG
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in QTc on ECG
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in QTc on ECG
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in heart rate on ECG
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in heart rate on ECG
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in heart rate on ECG
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in heart rate on ECG
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Number of subjects with changes in physical examination
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Number of subjects with changes in physical examination
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Number of subjects with changes in physical examination
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Number of subjects with changes in physical examination
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Adverse events
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Adverse events
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Adverse events
|
Day 15
|
Tolerability and Safety
Time Frame: Day 20-25
|
Adverse events
|
Day 20-25
|
Tolerability and Safety
Time Frame: Day 1
|
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
|
Day 1
|
Tolerability and Safety
Time Frame: Day 8
|
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
|
Day 8
|
Tolerability and Safety
Time Frame: Day 15
|
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
|
Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Screening (Diagnostic biopsy)
|
Androgen receptor expression
|
Screening (Diagnostic biopsy)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Day 16/17 (Radical prostatectomy sample)
|
Androgen receptor expression
|
Day 16/17 (Radical prostatectomy sample)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Screening (Diagnostic biopsy)
|
Extent of proliferation using Ki67
|
Screening (Diagnostic biopsy)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Day 16/17 (Radical prostatectomy sample)
|
Extent of proliferation using Ki67
|
Day 16/17 (Radical prostatectomy sample)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Screening (Diagnostic biopsy)
|
Extent of inflammation using leukocyte markers
|
Screening (Diagnostic biopsy)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Day 16/17 (Radical prostatectomy sample)
|
Extent of inflammation using leukocyte markers
|
Day 16/17 (Radical prostatectomy sample)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Screening (Diagnostic biopsy)
|
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
|
Screening (Diagnostic biopsy)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Day 16/17 (Radical prostatectomy sample)
|
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
|
Day 16/17 (Radical prostatectomy sample)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Screening (Diagnostic biopsy)
|
Treatment induced change in RNA transcriptome assessed by RNA sequencing
|
Screening (Diagnostic biopsy)
|
Histo-pathological and molecular changes in prostate tumor tissue samples
Time Frame: Day 16/17 (Radical prostatectomy sample)
|
Treatment induced change in RNA transcriptome assessed by RNA sequencing
|
Day 16/17 (Radical prostatectomy sample)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel Eberli, Prof., Klinik für Urologie, UniversitätSpital Zürich (USZ)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDPK67b-2002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on MDPK67b
-
Med Discovery SACompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted